Oct 13, 2026, 6:30 AM EDT · 4 weeks ago Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness
2026-10-06T10:41:16.000Z · 5 weeks ago Bluejay Diagnostics announces SYMON-II clinical validation study details
Oct 6, 2026, 6:30 AM EDT · 5 weeks ago Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock
2026-09-08T10:35:07.000Z · 2 months ago Bluejay Diagnostics and Lovell Government partner to access federal healthcare
Sep 8, 2026, 6:30 AM EDT · 2 months ago Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets
Aug 13, 2026, 6:00 AM EDT · 3 months ago Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
Jul 21, 2026, 6:30 AM EDT · 3 months ago Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
2026-06-17T21:25:09.000Z · 4 months ago Bluejay Diagnostics files to sell 11.22M shares of common stock for holders
Jun 5, 2026, 8:13 PM EDT · 5 months ago Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Jun 2, 2026, 12:19 PM EDT · 5 months ago Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
2026-06-02T10:45:59.000Z · 5 months ago Bluejay Diagnostics, Argonaut Manufacturing Services announce partnership
Jun 2, 2026, 6:30 AM EDT · 5 months ago Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
May 7, 2026, 4:01 PM EDT · 6 months ago Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
2026-04-07T10:45:34.000Z · 7 months ago Bluejay Diagnostics reaches 624 patient enrollment in Symphony clinical trial
Apr 7, 2026, 6:30 AM EDT · 7 months ago Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
Mar 12, 2026, 6:30 AM EDT · 8 months ago Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
2026-03-11T13:35:11.000Z · 8 months ago NorthStrive Fund urges Bluejay to evaluate strategic opportunity
Mar 11, 2026, 9:29 AM EDT · 8 months ago NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics
2026-03-06T11:41:51.000Z · 8 months ago Bluejay Diagnostics says SYMON II study ‘progressing as planned’
Feb 20, 2026, 6:30 AM EST · 8 months ago Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised
Feb 17, 2026, 6:30 AM EST · 8 months ago Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026
2025-12-29T12:05:14.000Z · 10 months ago Bluejay Diagnostics completes commercial-scale IL-6 antibody production
Dec 29, 2025, 7:00 AM EST · 10 months ago Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production
2025-10-23T21:05:24.000Z · 1 year ago Bluejay Diagnostics files to sell 6.93M shares of common stock for holders
Oct 10, 2025, 5:16 PM EDT · 1 year ago Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2025-10-09T19:20:15.000Z · 1 year ago Bluejay Diagnostics announces $4.5M private placement priced at-the-market
Oct 9, 2025, 3:15 PM EDT · 1 year ago Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Oct 9, 2025, 6:30 AM EDT · 1 year ago Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform
Aug 7, 2025, 6:30 PM EDT · 1 year ago Bluejay Diagnostics Provides Second Quarter Business and Corporate Update
Jun 3, 2025, 4:05 PM EDT · 1 year ago Bluejay Diagnostics Provides Mid-Year Business and Corporate Update
Apr 15, 2025, 7:00 AM EDT · 1 year ago Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting
Apr 7, 2025, 5:21 PM EDT · 1 year ago Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds
Jun 28, 2024, 11:32 AM EDT · 2 years ago Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
Jun 26, 2024, 8:00 AM EDT · 2 years ago SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients
Jan 2, 2024, 5:58 PM EST · 2 years ago Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering
Dec 28, 2023, 8:00 AM EST · 2 years ago Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering
Dec 27, 2023, 9:00 AM EST · 2 years ago Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)
Nov 9, 2023, 4:05 PM EST · 3 years ago Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results
Aug 25, 2023, 8:00 AM EDT · 3 years ago Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Aug 16, 2023, 7:00 AM EDT · 3 years ago Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results
May 19, 2023, 7:00 AM EDT · 3 years ago Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy
May 10, 2023, 7:30 AM EDT · 3 years ago Bluejay Diagnostics Reports First Quarter 2023 Financial Results
Feb 16, 2023, 8:00 AM EST · 3 years ago Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America
Nov 9, 2022, 8:00 AM EST · 4 years ago Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results
Aug 30, 2022, 4:05 PM EDT · 4 years ago Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 16, 2022, 7:30 AM EDT · 4 years ago Bluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory Failure
Jul 27, 2022, 7:30 AM EDT · 4 years ago Positive Clinical Results for Bluejay's Symphony IL-6 Test Presented at AACC 2022
Jul 26, 2022, 4:30 PM EDT · 4 years ago Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results
Jul 6, 2022, 7:30 AM EDT · 4 years ago Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test
Apr 20, 2022, 4:10 PM EDT · 4 years ago Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results
Mar 28, 2022, 7:00 AM EDT · 4 years ago Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance
Mar 24, 2022, 7:00 AM EDT · 4 years ago Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer
Mar 10, 2022, 7:00 AM EST · 4 years ago Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Jan 31, 2022, 7:00 AM EST · 4 years ago Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA
Jan 13, 2022, 11:29 AM EST · 4 years ago Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care
Jan 5, 2022, 8:15 AM EST · 4 years ago Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor
Dec 16, 2021, 9:11 AM EST · 4 years ago Bluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results
Nov 10, 2021, 8:15 AM EST · 5 years ago Bluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering